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PMH16
PREDICTORS OF HIGH COSTS FOR GENERALIZED ANXIETY
DISORDER WITH OR WITHOUT PAIN
Zhu B, Zhao Z,Ye W, Swindle R
Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: To identify predictors for high treatment costs in
individuals diagnosed with Generalized Anxiety Disorder (GAD)
with or without pain. METHODS: This analysis was conducted
using the PharMetrics Integrated Outcomes Database. Indivi-
duals aged 18–64 diagnosed with GAD (ICD9-CM: 30002)
between 1/2003 and 6/2004 who had continuous eligibility 6-
month prior and 1-year following GAD diagnosis were identi-
ﬁed. Annual treatment costs during the year after GAD diagnosis
were examined. The highest spenders (top 10%) of patients were
compared with the rest on demographics, medication use and
costs. Logistic regressions were used to identify predictors for
high treatment costs. Patients with pain or without pain were
examined separately. RESULTS: A total of 36,435 patients (67%
female, mean age 41.5 years) were included in this analysis. The
mean treatment costs were $49,248 for the top 10% spenders
and $3836 for the rest. The top10% spenders accounted for
58.8% of the total costs. Patients with pain (N = 22,133) were
associated with higher costs than those without pain (N =
14,302) ($11,445 vs. $3630, p < 0.001). Logistic regressions
revealed signiﬁcant risk factors for high costs including diagnoses
of schizophrenia (odds ratio (OR) = 2.03, p < 0.001), diabetes
(OR = 1.61, p < 0.001), asthma (OR = 1.55, p < 0.001), neuro-
pain (OR = 1.48, p < 0.001), musculoskeletal pain (OR = 1.46,
p < 0.001), depression (OR = 1.31, p < 0.001), and alcohol abuse
(OR = 1.66, p < 0.001); prior utilization of narcotics (OR = 1.62,
p < 0.001), emergence services (OR = 1.57, p < 0.001), hospi-
talizations (OR = 1.60, p < 0.001). Similar predictors were
obtained for GAD with pain but fewer predictors for GAD
without pain. CONCLUSION: This analysis showed that the top
10% spenders of GAD patients consumed nearly 60% of the
total costs. GAD patients with pain incurred nearly 3 times as
much cost as GAD patients without pain. The presence of prior
pain, depression, other comorbidities, and prior resource uti-
lization were signiﬁcant predictors for high treatment costs.
Special attention should be paid to those high costly patients in
management of GAD.
PMH17
TREATMENT COSTS OF COMORBID GENERALIZED ANXIETY
DISORDER, DEPRESSION AND PAIN
Zhao Z, Zhu B,Ye W, Swindle R
Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: To assess the impact of comorbid depression and
pain on treatment costs for individuals diagnosed with General-
ized Anxiety Disorder (GAD). METHODS: Using the PharMet-
rics Integrated Outcomes Database, individuals were included in
the study if they were: diagnosed with GAD (ICD9-CM: 30002)
between 1/2003 and 6/2004 (the diagnosis date as the index
date); no diagnosis of GAD 6-month prior the index date; con-
tinuously eligible for insurance coverage for 6-month prior and
12-month post the index date; and 18–64 years old. Total and
component treatment costs during the year following GAD diag-
nosis were compared among four patient groups: GAD only;
GAD/depression; GAD/pain; and GAD/depression/pain. General
Linear Models (GLM) controlling patient demographics (age,
gender, region and type of insurance plan), clinical characteris-
tics (provider specialty and other comorbidities), and prior costs
were used to evaluate the marginal impact of comorbid depres-
sion and/or pain on treatment costs. RESULTS: Of 36,435
patients (mean age 41.5 years; 67% female) included in this
study, 23.8% were GAD only, 15.5% GAD/depression, 32.8%
GAD/pain, and 28.0% GAD/depression/pain. The average total
annual treatment costs were $8377 for all patients. Results from
GLM regressions showed that compared to patients with GAD
only, total treatment costs were $837 higher for GAD patients
with depression (p < 0.001), $3429 higher for GAD patients with
pain (p < 0.001), and $7503 higher for those with both depres-
sion and pain (p < 0.001). Similar results were also found for
component costs including inpatient and outpatient costs. CON-
CLUSION: This study demonstrated that the majority of GAD
patients also suffered from depression or pain and a large portion
had both depression and pain. Comorbid depression and pain
had signiﬁcant impact on treatment costs, especially those with
pain or with both depression and pain. This suggested that an
optimal treatment strategy of GAD needs to take comorbid
depression and pain into consideration.
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OBJECTIVES: This study determined incremental Medicaid
expenditures associated with dementia among Indiana 
Medicaid recipients in 2004. METHODS: Analysis of Indiana
Medicaid claims and enrollment ﬁles was conducted. Sample
inclusion criteria were being at least 40 years old and having
Indiana Medicaid eligibility in 2004. Twenty-six ICD-9 diagno-
sis codes determined in a prior study to be speciﬁc for dementia
were used to identify dementia. Regression models were devel-
oped to estimate incremental expenditures in U.S. dollars.
Assessment of model ﬁt was used to select from OLS regression,
OLS on log of response variables, generalized linear negative
binominal, and zero-inﬂated negative binomial models. Based on
ﬁt and Voung statistics, zero-inﬂated negative binomial regres-
sion was used to ﬁt separate models for total expenditures and
expenditure subcategories. Models included covariates for age,
gender, race, marital status, geographic region, months of Med-
icaid eligibility, months of spend-down in effect, months of
Medicare coverage, mortality, and Charlson comorbidity index
score. RESULTS: A total of 145,684 individuals meeting inclu-
sion criteria were identiﬁed, 18,950 (13%) had dementia. Indi-
viduals with dementia had more comorbidity, were older, and
were more likely to be female, white, unmarried, and to die
during the study period. After adjusting for covariates, Indiana
Medicaid spent, mean (standard error), $9829 (211) p < 0.001,
more per recipient with dementia in incremental expenditures
associated with the disease. Much of the incremental expendi-
tures were due to nursing home expenditures $9154 (141) p <
0.001. Drug expenditures accounted for the second largest com-
ponent of the incremental expenditures $970 (37) p < 0.001, fol-
lowed by inpatient expenditures $211 (23) p < 0.001 and other
medical expenditures $128 (57) p < 0.05. Dementia was associ-
ated with lower outpatient expenditures $−78 (2.50) p < 0.001.
CONCLUSION: Incremental Medicaid expenditures associated
with dementia were substantial even after adjusting for other risk
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factors and accounted for $186 million or 8% of 2004 Indiana
Medicaid expenditures.
PMH19
A COMPARISON OF TOTAL DIRECT MEDICAL COSTS TO
MANAGED CARE OF ESCITALOPRAM VERSUS VENLAFAXINE
XR TREATMENT IN MAJOR DEPRESSIVE DISORDER
Erder MH,Wang C, Jonas JM
Forest Research Institute, Jersey City, NJ, USA
OBJECTIVES: To compare from a managed care perspective the
total direct medical costs of escitalopram (a selective serotonin
reuptake inhibitor) and venlafaxine XR (a serotonin-norepi-
nephrine reuptake inhibitor) as the ﬁrst-line therapy for major
depressive disorder (MDD). METHODS: A cost minimization
model that assumes no differences in study clinical outcomes was
developed, based on data from a randomized, double-blind, ﬁxed
dose clinical trial of escitalopram 20 mg/day (n = 98) and ven-
lafaxine XR 225 mg/day (n = 100). Ofﬁce visits required to treat
adverse events and to manage switching for patients who drop
out were modeled. Treatment costs for AEs and ofﬁce visit costs
were taken from the literature and professional opinion. Costs
for escitalopram and venlafaxine XR were assumed at average
wholesale price (AWP), discounted 20% for managed care orga-
nizations, $2.81/day (20 mg) and $3.83/day (150 mg), respec-
tively; the costs for concomitant medications were obtained from
the Red Book (2006) and drugstore.com. RESULTS: There were
statistically signiﬁcantly more dropouts due to AEs with ven-
lafaxine-XR than with escitalopram (16% and 4%, respectively;
P < 0.01). According to this cost minimization model, treatment
costs per patient with escitalopram are $227 vs. $301 with ven-
lafaxine XR. This cost saving of 25% for escitalopram was
obtained due to lower drug costs ($93 vs. $156 per patient),
lower AE costs ($14 vs. $19 per patient) and lower drug switch-
ing cost ($39 vs. $63 per patient). One-way sensitivity analysis
assuming either no AE withdrawals, or no AEs in the venlafax-
ine XR treatment arm, showed escitalopram treatment results in
cost savings of 19% and 20%, respectively. CONCLUSION:
Based on this analysis, switching 100 MDD patients treated with
venlafaxine XR to escitalopram offers costs savings to managed
care, estimated at $7475. These cost savings could be used to
treat 33 additional patients with escitalopram at an average total
cost of $227 per patient.
PMH20
THE ECONOMIC COSTS TO MANAGED CARE
ORGANIZATIONS OF EXCESS MD WITHDRAWAL FROM
DULOXETINE TREATMENT: AN OPPORTUNITY COSTS
MODEL
Erder MH,Wang C, Jonas JM
Forest Research Institute, Jersey City, NJ, USA
OBJECTIVES: Formulary decisions by managed care organiza-
tions (MCOs) can affect choice of drug treatment for major
depressive disorder (MDD). Drugs with poor tolerability may
impact cost of treatment due to treatment withdrawal; however,
the direct costs to MCOs of withdrawal from treatment have
rarely been estimated. The objective of this study was to estimate
the opportunity costs associated with excess patient withdrawal
with duloxetine versus escitalopram treatment from an MCO
perspective. METHODS: An opportunity cost model was con-
structed to estimate the cost of treatment withdrawals from a
prospective randomized clinical trial comparing escitalopram
(10–20 mg/day, n = 137) and duloxetine (60 mg/day, n = 133).
Proportional hazard analysis of patient disposition demonstrated
a 28% excess risk of withdrawal in the duloxetine arm after 8
weeks of treatment. The model assumes that all resources used
by patients who withdraw are wasted: 30 days of initial treat-
ment drug supplies, costs of switching to another drug, and treat-
ment of AEs for withdrawn patients. The model is based on 100
patients/arm and calculates the costs associated with 28 cases of
excess withdrawals. Treatment costs for AEs were taken from
the literature and professional opinion. Duloxetine costs were
assumed at average wholesale price (AWP), discounted 20% for
MCOs: $3.84/day (60 mg); medications costs were obtained
from the Red Book (2006) and drugstore.com. RESULTS: The
total opportunity costs are approximately $9000 ($321 per with-
drawn patient): $2500, drug costs; $4400, switching costs; and
$2000, treatment costs for AEs. One-way sensitivity analyses
included accounting for three all-cause hospitalizations 
(total costs of $22,800) increased mean opportunity cost to
$1135/withdrawn patient; assuming 50% reduction in switching
costs resulted in mean opportunity costs of $242/withdrawn
patient and reducing drug supply to 15 wasted days lowered
mean opportunity costs to $275/withdrawn patient. CONCLU-
SION: Choosing treatments with excess patient withdrawals
imposes an avoidable economic burden on MCOs.
PMH21
ANALYSIS OF DRUG TREATMENT PATTERNS, SERVICE 
USE AND COSTS ASSOCIATED WITH SPECIFIC
PHARMACOLOGICAL TREATMENTS FOR MAJOR 
DEPRSSIVE DISORDER
Becker MA1, Jones M2, Patel T1
1University of South Florida,Tampa, FL, USA, 2Eli Lilly and Company,
Indianopolis, IN, USA
OBJECTIVES: While controlling for relevant and possibly con-
founding variables this study examined antidepressant treatment
patterns for Florida Medicaid recipients with a diagnosis of
MDD. The objective was to identify the types of antidepressant
medication being prescribed including tricyclic antidepressants
(TCAs), selective serotonin reuptake inhibitors (SSRIs), sero-
tonin and nor-epinephrine reuptake inhibitor (SNRIs) (e.g.Ven-
lafaxine and Duloxetine) and Bupropion. Dosage patterns and
the factors that predict service use and costs among recipients of
antidepressant therapy were analyzed. METHODS: The sample
included 25,306 patients with a diagnosis of MDD who were
enrolled in the Florida Medicaid Program during FY03-05. The
research used three years of Medicaid claims data to compare
patient demographics, diagnostic characteristics, antidepressant
medication use, index dosage and service expenditure patterns 6
months prior to and one year after the index prescription event
for antidepressant medication users. RESULTS: Among those
persons diagnosed with MDD, the majority (84.5%) received
SSRIs alone or in combination with other antidepressants,
29.2% received SNRIs alone or in combination with other anti-
depressants and 15.3% received TCAs alone or in combination
with other antidepressants. A large majority (86.5%) were also
receiving prescription pain medication. Of these, more than half
were receiving prescription narcotics. Predictors of increased
service use and cost following initiation of antidepressant treat-
ment included older age, female sex, and pre-index prescription
costs. Results showed that physical health care costs increased
after switching to any antidepressant, however behavioral health
costs tended to decrease for all treated patients overtime with the
most dramatic decreases occurring in inpatient services. CON-
CLUSION: Current data on patterns, predictors and outcomes
of antidepressant medication provided to patients with MDD are
important to understand the care provided, promote optimal
clinical practice and improve quality of care.
